Previous 10 | Next 10 |
Last week, Dr. Dipak Bhatt, Amarin’s ( AMRN ) lead investigator for the Reduce-IT trial, published a report , along with other authors, on factual errors present in the recent judgment by Judge Miranda Du. The report discussed a single critical error - “As we will show, a key pi...
It’s no secret the global pandemic is creating unprecedented market volatility. Companies racing for a vaccine like Moderna and Inovio have seen their market valuations soar and then fall with every new headline. However, a number of companies focused on developing innovative new drug ...
Update : The following strategy article was written around 10 days ago and provided to TPT members. Since then, there has been a single significant change - the FDA has approved an ANDA from Hikma, bringing generic competition closer to the market. This news, in its turn, has had two major ...
Amarin (NASDAQ: AMRN ) intends to increase the promotion and education initiatives regarding VASCEPA (icosapent ethyl) as the only FDA-approved drug for lowering the persistent cardiovascular risk beyond statin therapy for high-risk patients. More news on: Amarin Corporation plc, Healthc...
DUBLIN, Ireland and BRIDGEWATER, N.J., June 01, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced that it intends to increase the level and breadth of its promotion and education initiatives regarding VASCEPA® (icosapent ethyl). As early signs em...
There were two developments in Amarin’s ( AMRN ) fight to keep generic versions of Vascepa (icosapent ethyl) from launching that we first reported on last week. First, we now find a New Clinical Investigation Exclusivity for the drug’s expanded cardiovascular risk indication on ...
Millions of Americans who would like to lower their risk of a heart attack could have a new, low-cost option to help them. On Friday, the FDA approved 1 gram Icosapent Ethyl Capsules from Hikma Pharmaceuticals (OTC: HKMPY) . Hikma's capsules are the generic equivalent of Vascepa from ...
Recon Technology (NASDAQ: RCON ) -38% on ~$2.1M registered direct offering . More news on: Recon Technology, Ltd., Geron Corporation, Syndax Pharmaceuticals, Inc., Stocks on the move, , Read more ...
In the earlier article covering the first argument, readers asked me why I thought a cross-species translation may be easier to consider than an intra-species translation like from those with mild to moderate hypertriglyceridemia to those with severe TGL. And the answer is provided in the br...
Amarin (NASDAQ: AMRN ) is collaborating with HLS Therapeutics to study Vascepa's effects on inflammatory biomarkers in those with COVID-19. More news on: Amarin Corporation plc, Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...